|
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for proven healthcare advice, travels to or treatment by using a genuine medical doctor. We are not physicians. Always confer with your doctor on Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical research trials and Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype healthcare trials take place in many of cities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectiveness of new drugs. The function of the studies / undertakings is to answer specific human medical questions. Clinical trials are a popular means for mDs, government agencies, and private sector companies to find treatments for all forms of conditions, including Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype. Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype Clinical Trials and other clinical trials allow for volunteers to access medical treatment alternatives before they are available to the masses. Many times the test subjects undergo treatment for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype clinical trial. Test subjects oftentimes recieve the best healthcare possible for their Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype condition. Hazards are a reality, nonetheless, and might include additional or frequent doctor trips, healthcare hazards (perhaps life-jeopardizing), and/or the treatment being ineffective. Trials are federally regulated with rigid guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "V" Clinical Trials Conditions > Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype  Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
For Condition: B Cell Lymphoma,Follicular Lymphoma,Neoplasm
Status: No longer recruiting
Sponsor(s): National Cancer Institute (NCI) ,
Synopsis: Patients undergo chemotherapy until remission is obtained, or disease has been stable for two cycles of chemotherapy, or progressive disease develops. Three to six months after completion of chemotherapy, patients who have achieved complete clinical remission or minimal disease status receive a series of 5 injections (given 1-2 months apart) of a vaccine consisting of 0.5 mg autologous tumor-derived immunoglobulin (Id) conjugated to KLH. The vaccine is administered with subcutaneous QS-21 as an immunological adjuvant.
Details: The idiotype of the immunoglobulin on a given B cell malignancy (Id) can serve as a clonal marker, and a previous pilot study in lymphoma patients has demonstrated that autologous Id protein can be formulated into an immunogenic, tumor specific antigen by conjugation to a carrier protein (KLH) and administration with an emulsion-based adjuvant. The objectives of this study are: 1) to evaluate feasibility and toxicity of new vaccine formulations, and 2) to evaluate cellular and humoral immune responses against the unique idiotype of the patient's lymphoma. The goal of this study is to treat patients with follicular lymphomas to complete remission or minimal residual disease with chemotherapy. Six to twelve months after completion of chemotherapy, in an effort to reduce the relapse rate (by eradicating microscopic disease resistant to chemotherapy), patients will receive one of two new formulations of an autologous Id vaccine.
Eligibility:
Study Type: Interventional, Treatment, Safety
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: INCLUSION CRITERIA: Sex: Male and female. Age: Patients must be greater than or equal to 18 years old. Patients must meet all of the following eligibility criteria: Tissue diagnosis of: follicular small cleaved cell or follicular mixed lymphoma with surface IgM, IgA, or IgG phenotype with a monoclonal heavy and light chain. Stage III or IV lymphoma. A single peripheral lymph node of at least 2x2 to 3x3 cm size and accessible for biopsy/harvest. Karnofsky status greater than or equal to 70%. Life expectancy of greater than 1 year. Serum creatinine less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma. Bilirubin less than or equal to 1.5 mg/dl unless felt to be secondary to lymphoma or Gilbert's disease. SGOT/SGPT less than or equal to 3.5 upper limit of normal. Ability to give informed consent. Ability to return to clinic for adequate follow-up for the period that the protocol requires. EXCLUSION CRITERIA: The presence of any exclusion criteria listed below will prohibit entry onto protocol: Prior total body irradiation. Presence of antibodies to HIV or hepatitis B surface agents or other active infectious process. Pregnant or lactating. Fertile men and women must plan to use an effective contraception. A beta-HCG level will be obtained in women of child-bearing potential. Patients with previous or concomitant malignancy, regardless of site, except curatively treated squamous or basal cell carcinoma of the skin, or effectively treated carcinoma in situ of the cervix. Patients unwilling to give informed consent. Any medical or psychiatric condition that in the opinion of the protocot chairman would compromise the patient's ability to tolerate treatment. Patients with CNS lymphoma (current or previously treated) will not be eligible.
Total Enrollment: 30
Location and Contact Information:
National Cancer Institute (NCI)
Bethesda, Maryland, 20892
United States
Additional Information:
Study ID Numbers: 970077; 97-C-0077
Study Start Date: January 30, 1997
Record last reviewed: January 1, 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00001572
Other Neoplasm Studies:
1. Treatment of Patients with Cancer with Genetically Modified Salmonella Typhimurium Bacteria
2. Total Body Irradiation for Bone Marrow Transplants: Collaborative Efforts
3. Phase 1 Study of Imatinab (STI571) in Patients with Advanced Cancer and Liver Dysfunction
4. Continuing Care and Treatment for Patients with Cancer/AIDS/Skin Disease
5. Induction of Suction Blisters in Patients with Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers
Related Studies:
Other Neoplasm Clinical Trials
Other Maryland Clinical Trials
Other Bethesda Clinical Trials
Vaccination of Follicular Lymphomas with Tumor-Derived Immunoglobulin Idiotype
|
|
|
|
|
|
|
|
